… Overall, among 342 patients with advanced lung cancer considered for nivolumab therapy,
a total of 260 patients were selected. Thirty two patients, who applied for the nivolumab …

… -cell lung cancer and was associated with a manageable safety profile, consistent with
previous studies. Our results suggest that nivolumab … non-small-cell lung cancer, and should be …

… MDX-1106 phase I study evaluated the safety of nivolumab in patients … cancer, renal cell
cancer, and NSCLC [Citation12]. A total of 39 patients were included, who received nivolumab …

… Nivolumab, an immune checkpoint inhibitor, is now a … -cell lung cancer based on the results
from phase III clinical trials. We evaluated the real-world efficacy and safety of nivolumab in a …

… Nivolumab has been shown to be effective and safe in previously treated patients with advanced
non-small cell lung cancer … Furthermore, nivolumab efficacy is unknown in patients who …

… , demonstrated robust efficacy and a manageable safety profile across multiple tumor types
… efficacy and safety of nivolumab for pretreated patients with non-small cell lung cancers in …

… that treatment with nivolumab beyond progression is feasible and safe, and that reduction
or stabilization of target lesions may occur when patients continue nivolumab after initial …

… We evaluated the efficacy and lung toxicity of nivolumab in patients with NSCLC and …
nivolumab by measuring the response rate (RR), progression-free survival (PFS) duration, and lung …

… Apart from skin and breast cancers, lung cancer is the most commonly diagnosed cancer in
… In this article, we review the pharmacology as well as the safety and efficacy of nivolumab in …

… of lung cancer and initiating treatment with nivolumab were … small cell lung cancer (NSCLC)
who received ≥1 nivolumab … of nivolumab initiation and its effectiveness and safety after a …